The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Open Access
- 1 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (1), 29-38
- https://doi.org/10.1215/15228517-2006-025
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trialInvestigational New Drugs, 2005
- Toward better early-phase brain tumor clinical trials: A reappraisal of current methods and proposals for future strategiesNeuro-Oncology, 2002
- A phase III study of radiation therapy plus carmustine with or without recombinant interferon-? in the treatment of patients with newly diagnosed high-grade gliomaCancer, 2001
- On the Use of Surrogate End Points in Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 2000
- Response and progression in recurrent malignant gliomaNeuro-Oncology, 1999
- Response and progression in recurrent malignant gliomaNeuro-Oncology, 1999
- Phase II study of amonafide in patients with recurrent gliomaJournal of Neuro-Oncology, 1995
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychological Bulletin, 1968
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958